Moderna (MRNA) has agreed to pay up to $2.25 billion to Roivant Sciences Ltd. (ROIV) to settle intellectual property claims related to the lipid nanoparticle technology used in its COVID-19 vaccine. The agreement prevents a jury trial that was scheduled to begin next week.